The Benchmark Company Maintains Speculative Buy Rating and $7 PT on Columbia Laboratories

A report from The Benchmark Company reiterates its Speculative Buy rating and $7 price target on Columbia Laboratories CBRX. The report states, “October 28 at the ACOG District-2 meeting in New York City, Dr. Roberto Romero presented new information about the PREGNANT study and discussed Michigan Medicaid's plan to reimburse for universal cervical screening and progesterone gel as medically necessary to prevent preterm birth in pregnancies involving short cervix. Michigan Medicaid currently reimburses for Crinone for prevention of preterm birth and North Carolina, Mississippi and Idaho Blue Cross plans have recently adopted national Blue Cross guidance to reimburse." CBRX closed Friday at $2.68.